Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28499583

Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2017 Jun
First author
Gronchi A

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Jun;18(6):706-707. doi: 10.1016/S1470-2045(17)30330-3.
    note
    Source null
    related pmid
    28593841
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2017 Jun;18(6):e301. doi: 10.1016/S1470-2045(17)30371-6.
    note
    Source null
    related pmid
    28593858
    relationship
    Erratum in
  3. citation
    Nat Rev Clin Oncol. 2017 Oct;14(10):589-590. doi: 10.1038/nrclinonc.2017.118.
    note
    Source null
    related pmid
    28786415
    relationship
    Comment in

Authors and identifiers

  1. name
    Gronchi A
    type
    Author
  2. name
    Ferrari S
    type
    Author
  3. name
    Quagliuolo V
    type
    Author
  4. name
    Broto JM
    type
    Author
  5. name
    Pousa AL
    type
    Author
  6. name
    Grignani G
    type
    Author
  7. name
    Basso U
    type
    Author
  8. name
    Blay JY
    type
    Author
  9. name
    Tendero O
    type
    Author
  10. name
    Beveridge RD
    type
    Author
  11. name
    Ferraresi V
    type
    Author
  12. name
    Lugowska I
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Gronchi A
    type
    Author
  2. name
    Ferrari S
    type
    Author
  3. name
    Quagliuolo V
    type
    Author
  4. name
    Broto JM
    type
    Author
  5. name
    Pousa AL
    type
    Author
  6. name
    Grignani G
    type
    Author
  7. name
    Basso U
    type
    Author
  8. name
    Blay JY
    type
    Author
  9. name
    Tendero O
    type
    Author
  10. name
    Beveridge RD
    type
    Author
  11. name
    Ferraresi V
    type
    Author
  12. name
    Lugowska I
    type
    Author
bibliography ids
  1. nci-bib-563c741cef0332c137792451
book metadata
content sha256
ece50f55c07059cb7fe41aa0bbc52df0f53e14f4a2e98f8f5aecdf529c66a8e5
document type
citation
dois
  1. 10.1016/S1470-2045(17)30334-0
electronic publication date
display
2017 May 9
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28499583
immutable id
pubmed:28499583@ece50f55c07059cb7fe41aa0bbc52df0f53e14f4a2e98f8f5aecdf529c66a8e5
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
6
name
The Lancet. Oncology
nlm unique id
100957246
pages
812-822
volume
18
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Jun;18(6):706-707. doi: 10.1016/S1470-2045(17)30330-3.
    note
    Source null
    related pmid
    28593841
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2017 Jun;18(6):e301. doi: 10.1016/S1470-2045(17)30371-6.
    note
    Source null
    related pmid
    28593858
    relationship
    Erratum in
  3. citation
    Nat Rev Clin Oncol. 2017 Oct;14(10):589-590. doi: 10.1038/nrclinonc.2017.118.
    note
    Source null
    related pmid
    28786415
    relationship
    Comment in
outcomes validated
false
pmid
28499583
provenance
batch id
1c173f0e18be0c6d461b
provider
NCBI PubMed ESummary
record sha256
05c6ffd285cfb383b6310467db7adc0a92a578a6b1140743ca93deb142e6f1aa
response sha256
27a6f8bb5d49a8d376b07e1b1768913c558986bf73de92cdd65c8f05a5fa1e61
retrieved at
2026-09-09T23:47:25.975513+00:00
publication date
display
2017 Jun
precision
month
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28499583/
title
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.

Preserved source evidence · Not medical advice